Literature DB >> 2191763

Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Rectal Cancer Study Group.

.   

Abstract

From 1980 to 1987, 849 patients with clinically resectable rectal adenocarcinoma were randomized into a controlled clinical trial of radiation therapy (2500 cGy over 5 to 7 days) before surgery versus surgery alone. At a median follow-up time of 53 months (range, 8 to 90) the incidence of pelvic recurrence among 679 curatively operated upon patients was significantly lower among those allocated to radiation therapy (P less than 0.01). A reduction was observed in all Dukes' stages. No significant difference between the treatment groups was observed with regard to frequency of distant metastases or overall survival. Among all randomized patients as well as the radically operated patients the recurrence-free interval, i.e., time to local recurrence or distant metastasis, was significantly prolonged in the preoperatively irradiated group. The radically operated patients also had a significantly prolonged survival related to rectal cancer (P = 0.05). The postoperative morbidity, however, was significantly higher among irradiated patients. The postoperative mortality was 8% in the radiation therapy group compared to 2% in the surgery alone group (P less than 0.01).

Entities:  

Mesh:

Year:  1990        PMID: 2191763     DOI: 10.1002/1097-0142(19900701)66:1<49::aid-cncr2820660111>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  52 in total

Review 1.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Acceptance of neoadjuvant short-term radiotherapy: a survey under surgeons and radiotherapists.

Authors:  Alexis Ulrich; Jessica Schwerdt; Kaspar Z'graggen; Peter Kienle; Jürgen Weitz; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2007-03-30       Impact factor: 3.445

Review 3.  Chemoradiotherapy and adjuvant chemotherapy for rectal cancer.

Authors:  Toshiaki Watanabe
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

4.  Pre-operative radiotherapy as adjuvant treatment in rectal cancer.

Authors:  F Izar; G Fourtanier; B Pradere; P Chiotasso; E Bloom; I Fontes-Dislaire; R Bugat; N Daly
Journal:  World J Surg       Date:  1992 Jan-Feb       Impact factor: 3.352

Review 5.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

6.  Comparison of treatment results between surgery alone, preoperative short-course radiotherapy, or long-course concurrent chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chung-Hung Yeh; Miao-Fen Chen; Chia-Hsuan Lai; Wen-Shih Huang; Steve P Lee; Wen-Cheng Chen
Journal:  Int J Clin Oncol       Date:  2011-09-22       Impact factor: 3.402

7.  Patterns of recurrence following pelvic exenteration and external radiotherapy for locally advanced primary rectal adenocarcinoma.

Authors:  P Luna-Perez; S Delgado; S Labastida; N Ortiz; D Rodriguez; L Herrera
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

Review 8.  Radiation treatment for rectal cancer.

Authors:  B J Cummings
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

9.  Redefining contraindications to laparoscopic colorectal resection for high-risk patients.

Authors:  John H Marks; Ulana B Kawun; Wajdi Hamdan; Gerald Marks
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

10.  Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study.

Authors:  Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans
Journal:  Int J Colorectal Dis       Date:  2008-12-03       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.